Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac^®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile.

ABSTRACT: During the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac^® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac^®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any loc

SUBMITTER: Le Corre N 

PROVIDER: S-EPMC10611329 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature